Backs FY24 revenue view $970M-$1.02B, consensus $1B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme announces Takeda receives approval for HYQVIA by MHLW
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
- Halozyme reports FDA approval for Opdivo co-formulated with Enhanze
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy